Welsis (WLSS) EBITDA Margin (2022 - 2023)
Welsis (WLSS) recorded quarterly EBITDA Margin of 613.25% in Q4 2023, down 22277.28% quarter-over-quarter from 2.77% in Q3 2023, and down 35008.0% on a YoY basis from N/an in Q4 2022.
Welsis (WLSS) EBITDA Margin (2022 - 2023) Analysis & Trends
Welsis' EBITDA Margin history runs 2 years deep, the most recent figure standing at 613.25% for Q4 2023.
- In Q4 2023, EBITDA Margin fell 35008.0% year-over-year to 613.25%; the TTM figure through Sep 2024 stood at 2894.9% (down 277170.0% YoY), while the FY2024 annual figure was 2894.9%, down 277493.0% from the prior year.
- EBITDA Margin was 613.25% for Q4 2023 at Welsis, down from 2.77% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2.77% in Q3 2023 to a low of 613.25% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 24.83 Bn | 17.52 Bn | 662.02 Mn | 26.39% |
| 2 | BrightSpring Health Services | 13.57 Bn | 12.69 Bn | 482.22 Mn | 3.36% |
| 3 | Healthequity | 7.20 Bn | 6.93 Bn | 256.31 Mn | 29.03% |
| 4 | Hinge Health | 5.42 Bn | 5.11 Bn | 154.23 Mn | 19.09% |
| 5 | 10x Genomics | 4.46 Bn | 3.92 Bn | 106.18 Mn | -11.30% |
| 6 | Doximity | 3.81 Bn | 3.06 Bn | 125.97 Mn | 17.08% |
| 7 | Waystar Holding | 3.52 Bn | 3.36 Bn | 268.04 Mn | 27.87% |
| 8 | Privia Health | 2.94 Bn | 2.57 Bn | 595.71 Mn | 1.25% |
| 9 | Omnicell | 1.76 Bn | 1.59 Bn | 140.36 Mn | 5.44% |
| 10 | Welsis | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -613.25% |
| Sep 30, 2023 | 2.77% |
| Jun 30, 2023 | -60.64% |
| Dec 31, 2022 | -263.17% |